Letter by Zhao et al Regarding Article, "Association Between Serum Bilirubin, Lipid Levels, and Prevalence of Femoral and Carotid Atherosclerosis: A Population-Based Cross-Sectional Study"
Yufei Zhao,Weiguo Fu,Lixin Wang
DOI: https://doi.org/10.1161/ATVBAHA.122.318939
2023-01-01
Abstract:HomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 43, No. 4Letter by Zhao et al Regarding Article, “Association Between Serum Bilirubin, Lipid Levels, and Prevalence of Femoral and Carotid Atherosclerosis: A Population-Based Cross-Sectional Study” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBLetter by Zhao et al Regarding Article, “Association Between Serum Bilirubin, Lipid Levels, and Prevalence of Femoral and Carotid Atherosclerosis: A Population-Based Cross-Sectional Study” Yufei Zhao, Weiguo Fu and Lixin Wang Yufei ZhaoYufei Zhao https://orcid.org/0000-0002-4918-2429 Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China (Y.Z., W.F., L.W.). Vascular Surgery Institute of Fudan University, Shanghai, China (Y.Z., W.F., L.W.). National Clinical Research Center for Interventional Medicine, Shanghai, China (Y.Z., W.F., L.W.). Search for more papers by this author , Weiguo FuWeiguo Fu Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China (Y.Z., W.F., L.W.). Vascular Surgery Institute of Fudan University, Shanghai, China (Y.Z., W.F., L.W.). National Clinical Research Center for Interventional Medicine, Shanghai, China (Y.Z., W.F., L.W.). Department of Vascular Surgery, Xiamen Branch, Zhongshan hospital, Fudan University, China (W.F., L.W.). Search for more papers by this author and Lixin WangLixin Wang https://orcid.org/0000-0002-1379-3906 Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China (Y.Z., W.F., L.W.). Vascular Surgery Institute of Fudan University, Shanghai, China (Y.Z., W.F., L.W.). National Clinical Research Center for Interventional Medicine, Shanghai, China (Y.Z., W.F., L.W.). Department of Vascular Surgery, Xiamen Branch, Zhongshan hospital, Fudan University, China (W.F., L.W.). Search for more papers by this author Originally published22 Mar 2023https://doi.org/10.1161/ATVBAHA.122.318939Arteriosclerosis, Thrombosis, and Vascular Biology. 2023;43:e121–e122To the Editor:We have read with great interest the impressive study by Su et al1 and would like to congratulate the authors for revealing the inversely association between serum bilirubin levels and the prevalence of carotid or femoral atherosclerosis, which could be mediated by LDL (low-density lipoprotein) and cholesterol. Although it seems that the highest levels of bilirubin reduced the odds of concurrent carotid and femoral atherosclerosis with a statistically significant P value, the current analyses should be treated cautiously with 2 concerns to be resolved.First, due to the excessive cholesterol accumulation in the vascular wall, a hallmark of atherosclerosis, the levels of circulating lipid indicators and bilirubin probably differ over the time,2 while investigators did not report when serum biochemical tests and comprehensive blood counts were taken. Is it performed before, at the time of, or after patients receiving ultrasound examination and then diagnosed with atherosclerosis? If the blood test occurred a long time before or after the ultrasound examination demonstrating carotid and peripheral atherosclerosis, the bilirubin levels may not precisely reflect the vascular health status and the atherosclerosis stage, and therefore, contribute to the potential bias.Second, indirect bilirubin binds to plasma albumin after released into the blood due to its lipid solubility.3 Therefore, circulating plasma albumin, which represents synthetic function of liver, could also affect the level of indirect bilirubin. Although, as authors stated, they excluded participants with self-reported history of liver disease, there is a chance that some participants barely get acquainted with their own physical health and the symptoms of liver diseases may appear insidiously, and thereby, those with low plasma albumin might be inappropriately included in the study. To avoid this possible bias, the level of circulating plasma albumin or combination of albumin-bilirubin4 could be tested between atherosclerosis and nonatherosclerosis group in order to further confirm or explain the current conclusion.Third, the HDL (high-density lipoprotein) is considered good cholesterol since it transports free cholesterol stored in tissues into the liver and reduces cholesterol deposition, playing an antiatherosclerosis role. The Framingham Heart Study confirmed that the concentration of high-density lipoprotein cholesterol is negatively correlated with the occurrence and severity of cardiovascular diseases, indicating individuals with low HDL levels are at increased risk of atherosclerosis, while those with high HDL levels are less likely to develop atherosclerosis.5–7 However, in Table 2, results from multinomial logistic regression models showed that participants with the highest tertile (group Q3) of serum HDL (n=166) were at increased odds of carotid atherosclerosis (OR, 1.15 [0.89–1.49]), compared with reference group Q1 (n=187). It is also weird that participants with the moderate tertile of serum HDL in group Q2 showed increased odds of carotid atherosclerosis (OR, 1.10 [0.87–1.40]) and femoral atherosclerosis (OR, 1.10 [0.88–1.38]) separately, though they were at diminished odds of concurrent carotid and femoral atherosclerosis (OR, 0.87 [0.67–1.13]). Since the number of participants in group Q2 and Q3 is less than that of group Q1, it is necessary to explain why the OR were greater than 1, and why the participants with high HDL, despite without statistically significance, seemed more likely to develop atherosclerosis. It may result from an over scattered data or peculiar outliers. Authors should further discuss and explain this issue.We appreciate the authors’ findings, but these results should be further interpreted and validated.Article InformationDisclosures None.FootnotesFor Disclosures, see page e122.References1. Su Q, Chen H, Du S, Dai Y, Chen C, He T, Feng R, Tao T, Hu Z, Zhao H, et al. Association between serum bilirubin, lipid levels, and prevalence of femoral and carotid atherosclerosis: a population-based cross-sectional study.Arterioscler Thromb Vasc Biol. 2023; 43:136–145. doi: 10.1161/ATVBAHA.122.318086LinkGoogle Scholar2. Song Y, Liu J, Zhao K, Gao L, Zhao J. Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseases.Cell Metab. 2021; 33:1911–1925. doi: 10.1016/j.cmet.2021.09.001CrossrefMedlineGoogle Scholar3. Danoff S, Grantz C, Boyer A, Holt LE. Conversion of indirect- to direct-reacting bilirubin in vivo.Science. 1958; 127:759–760. doi: 10.1126/science.127.3301.759CrossrefMedlineGoogle Scholar4. Fulgenzi CAM, Cheon J, D’Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for hcc in clinical practice: results of the ab-real study.Eur J Cancer. 2022; 175:204–213. doi: 10.1016/j.ejca.2022.08.024CrossrefMedlineGoogle Scholar5. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review.JAMA. 2007; 298:786–798. doi: 10.1001/jama.298.7.786CrossrefMedlineGoogle Scholar6. Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease.Am J Cardiol. 2001; 88:99n–913. doi: 10.1016/s0002-9149(01)02146-4CrossrefGoogle Scholar7. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The framingham study.Am J Med. 1977; 62:707–714. doi: 10.1016/0002-9343(77)90874-9CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails April 2023Vol 43, Issue 4 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/ATVBAHA.122.318939PMID: 36947605 Originally publishedMarch 22, 2023 PDF download Advertisement SubjectsPeripheral Vascular DiseaseVascular Disease